Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.
Alpha Tau Medical Ltd. (NASDAQ: DRTS) is a clinical-stage oncology therapeutics company developing Alpha DaRT, a localized alpha-radiation therapy for solid tumors. The DRTS news feed highlights the company’s clinical progress, regulatory interactions, manufacturing milestones, and financial updates related to this technology.
Recent news has focused on Alpha Tau’s expanding clinical program. The company has reported final results from a first-in-human pancreatic ductal adenocarcinoma study in Montreal, including disease control and response rates, and is running the IMPACT multi-center pilot trial in the United States combining Alpha DaRT with chemotherapy in newly diagnosed unresectable or metastatic pancreatic cancer. News items also cover pilot studies in recurrent glioblastoma multiforme, including the first reported Alpha DaRT treatment in the brain, as well as FDA-approved trials in locally recurrent prostate cancer.
Regulatory and pre-market developments are another frequent theme. Alpha Tau has announced submission of the first module of its pre-market approval application to the U.S. FDA for Alpha DaRT in recurrent cutaneous squamous cell carcinoma, under a modular PMA framework. The company also reports on Breakthrough Device Designations, participation in the FDA’s Total Product Life Cycle Advisory Program, and marketing authorization processes in other regions.
Operational and corporate updates appear regularly, including receipt of a radioactive material license for the company’s manufacturing facility in New Hampshire, participation in major healthcare and investor conferences, and periodic financial results with corporate commentary. Investors and observers can use the DRTS news page to follow key milestones in Alpha Tau’s efforts to advance Alpha DaRT through clinical development, regulatory review, and preparation for potential commercialization.
Alpha Tau Medical Ltd. (NASDAQ: DRTS) reported its first quarter 2022 financial results and updated on corporate milestones. The company raised approximately $104 million through its public debut in March 2022 and plans to initiate a pivotal U.S. trial for skin cancers mid-2022. Key highlights include a complete response rate of 100% in a pilot study for malignant skin cancer and significant advancements in manufacturing and supply chain capabilities. However, the company reported a net loss of $25.7 million, or ($0.54) per share, and expects its cash balance of $107 million to sustain operations for two years.
Alpha Tau Medical (Nasdaq: DRTS) has commenced treatment of its first patients in a French multicenter trial utilizing its innovative alpha-radiation therapy, Alpha DaRT™, for skin cancer. The trial, led by Dr. Pascal Pommier at the Leon Berard Center in Lyon, includes two cohorts focusing on newly diagnosed patients and those with recurrent disease. The main goal is to evaluate the overall response rate after treatment. CEO Uzi Sofer expressed excitement over the study, aiming to provide new treatment options for patients with limited alternatives.
On March 28, 2022, Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) reported its 2021 financial results, highlighting a significant 100% complete response rate in its U.S. pilot trial for skin cancer. The company received two FDA breakthrough device designations and successfully completed its merger with Healthcare Capital Corp, raising approximately $90 million. R&D expenses increased to $11.4 million, resulting in a net loss of $27.3 million for the year. As of December 31, 2021, Alpha Tau's cash reserves stood at $31.9 million, expected to sustain operations for two years.